Thiotepa


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intracavitary
Malignant effusions
Adult: Up to 60 mg in 20-60 mL of sterile water may be instilled after aspiration.
Elderly: Initiate at lower dose.

Intravenous
Breast cancer, Ovarian carcinoma
Adult: Dosage must be individualised. Usual range: 0.3-0.4 mg/kg via rapid IV admin every 1-4 wk. Avoid admin if WBC or platelet counts fall below acceptable levels. Stop treatment if WBC falls rapidly.
Elderly: Initiate at lower dose.

Intravesical
Bladder cancer
Adult: Up to 60 mg instilled in 30-60 mL of sterile water or sodium chloride 0.9% into the bladder of patient previously dehydrated for 8-12 hr and retained for 2 hr. Reposition patient every 15 minutes for max area contact. May be repeated once a wk for up to 4 wk. For prophylaxis of recurrence after surgical removal of bladder cancer: Up to 60 mg may be instilled at intervals of 1-2 wk, for up to 8 instillations.
Elderly: Initiate at lower dose.

Ophthalmic
Prophylaxis of recurrence of pterygium following surgical removal
Adult: As 0.05% eye drops in sterile Ringer's solution: Instill every 3 hr for up to 6 wk after surgical removal of pterygium to reduce the possibility of recurrence.

Urethral
Condyloma acuminata
Adult: Instill 60 mg wkly into urethra.
Elderly: Initiate at lower dose.
Renal Impairment
Dose adjustment may be needed.
Hepatic Impairment
Dose adjustment may be needed.
Hướng dẫn pha thuốc
Reconstituted by adding 1.5 ml of sterile water for injection to a vial containing 15 mg of the drug or 3 ml of sterile water for injection to a vial containing 30 mg of the drug. This produces a solution with 10 mg of thiotepa per mL which should be filtered with a pore size of 0.22 micron. Reconstituted solution is hypotonic and should be further diluted with 0. 9% sodium chloride before use. If larger volumes of solution are needed for intracavitary, IV infusion, or perfusion therapy, the reconstituted solution may be diluted with sodium chloride, dextrose, dextrose and sodium chloride, Ringer's or lactated Ringer's injection. For local admin, thiotepa may be mixed with 2% procaine hydrochloride inj and/or 0.1% (1:1000) epinephrine hydrochloride inj.
Tương kỵ
Y-site incompatibility: Minocycline, vinorelbine, cisplatin and filgrastim. Admixture incompatibility: Cisplatin.
Chống chỉ định
Pregnancy; lactation; hypersensitivity; severe myelosuppression with leukocyte count <3000 cells/mm3 or platelet count <150,000 cells/mm3.
Thận trọng
Elderly; child; preexisting renal, hepatic and bone marrow function impairment. Monitor for fever, chills, sore throat, discoloration of urine, black stools or unusual bleeding or easy bruising. Monitor blood counts before initiation, at least wkly during and at least 3 wk after discontinuation of therapy; monitor hepatic and renal function.
Phản ứng phụ
GI disturbances; fatigue, weakness, headache and dizziness; hypersensitivity reactions; blurred vision and conjunctivitis; amenorrhoea, impaired fertility; local irritation, frank chemical or haemorrhagic cystitis; depigmentation of periorbital skin (eye drops).
Potentially Fatal: Bone marrow depression, mutagenesis, teratogenesis and carcinogenesis.
Intracavitary/Intravesical/IT/IV/Parenteral: D
Quá liều
Overdosage symptoms are mainly extensions of common adverse reactions, especially leukopenia and thrombocytopenia, anaemia. No known antidote but whole blood or platelet transfusions have been beneficial in patients with haematopoietic toxicity. Thiotepa is removed by dialysis.
Tương tác
Concomitant use of other alkylating agents or irradiation enhance effect. Prolongs action of succinylcholine and other neuromuscular-blocking agents due to inhibition of plasma pseudocholinesterase. Increased risk of myelosuppression when used with colony-stimulating factors (such as filgrastim, lenograstim) 24 hr before to 24 hr after admin of cytotoxic chemotherapy. Coadmin with cyclophosphamide inhibit the metabolism of cyclophosphamide to its active metabolite and decrease both its efficacy and toxicity.
Food Interaction
Black cohosh, dong quai in oestrogen-dependent tumors.
Tác dụng
Description: Thiotepa is an ethyleneimine alkylating agent which interferes with DNA replication and transcription of RNA, resulting in the disruption of nucleic acid function. It is also immunosupressive. It may control malignant effusion by a direct antineoplastic effect after intracavitary admin. Low pH enhances reactivity of thiotepa. It has generally been replaced by cyclophosphamide and other drugs.
Pharmacokinetics:
Absorption: GI: incomplete and unreliable. IM: variable. Through serous membranes eg. the bladder and pleura: absorption to some extent.
Metabolism: Extenive metabolised to active and inactive metabolites.
Excretion: Excreted in urine as unchanged drug and metabolites.
Bảo quản
Intracavitary:
Unconstituted powder: Store at 2-8°C; reconstituted (with sterile water for injection): store in a fridge and use within 8 hr; reconstituted solutions further diluted with sodium chloride Injection: used immediately. Protect from light.
Intravenous:
Unconstituted powder: Store at 2-8°C; reconstituted (with sterile water for injection): store in a fridge and use within 8 hr; reconstituted solutions further diluted with sodium chloride Injection: used immediately. Protect from light.
Intravesical:
Unconstituted powder: Store at 2-8°C; reconstituted (with sterile water for injection): store in a fridge and use within 8 hr; reconstituted solutions further diluted with sodium chloride Injection: used immediately. Protect from light.
Ophthalmic:
Unconstituted powder: Store at 2-8°C.
Urethral:
Unconstituted powder: Store at 2-8°C; reconstituted (with sterile water for injection): store in a fridge and use within 8 hr; reconstituted solutions further diluted with sodium chloride Injection: used immediately. Protect from light.
Phân loại MIMS
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Thiotepa từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in